Doxorubicin hydrochloride | Tocris Bioscience 2252/10 product information

product summary

company name :

Tocris Bioscience

product type :

chemical

product name :

Doxorubicin hydrochloride

catalog :

2252/10

quantity :

10 mg (also 50 mg)

price :

211 USD

more info or order :

Tocris Bioscience product webpage

citations: 30

Reference
Alimirah F, Pulido T, Valdovinos A, Alptekin S, Chang E, Jones E, et al. Cellular Senescence Promotes Skin Carcinogenesis through p38MAPK and p44/42MAPK Signaling. Cancer Res. 2020;80:3606-3619 pubmed publisher
Yoon Lee J, Chung J, Hwa Kim K, Hyun An S, Yi J, Ae Kwon K, et al. Extracorporeal shock waves protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin via the integrin-ILK-Akt-Sp1/p53 axis. Sci Rep. 2019;9:12149 pubmed publisher
Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roche H, et al. Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. Cell Death Dis. 2019;10:199 pubmed publisher
Yoon M, Kang S, Lee S, Woo T, Oh A, Park S, et al. p53 induces senescence through Lamin A/C stabilization-mediated nuclear deformation. Cell Death Dis. 2019;10:107 pubmed publisher
Kanchanapally R, Deshmukh S, Chavva S, Tyagi N, Srivastava S, Patel G, et al. Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis. Int J Nanomedicine. 2019;14:531-541 pubmed publisher
Seo S, Min K, Woo S, Kwon T. Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin-mediated apoptosis through the induction of endoplasmic reticulum stress. Exp Mol Med. 2018;50:107 pubmed publisher
Iriondo O, Liu Y, Lee G, Elhodaky M, Jimenez C, Li L, et al. TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun. 2018;9:1994 pubmed publisher
Le Duff M, Gouju J, Jonchère B, Guillon J, Toutain B, Boissard A, et al. Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. Cell Death Dis. 2018;9:199 pubmed publisher
Ali R, Samman N, Al Zahrani H, Nehdi A, Rahman S, Khan A, et al. Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1. BMC Cancer. 2017;17:803 pubmed publisher
El Zawily A, McEwen E, Toosi B, Vizeacoumar F, Freywald T, Vizeacoumar F, et al. The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment. Sci Rep. 2017;7:14767 pubmed publisher
Ayoub N, Al Shami K, Alqudah M, Mhaidat N. Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. Onco Targets Ther. 2017;10:4869-4883 pubmed publisher
Gallagher L, Radhi O, Abdullah M, McCluskey A, Boyd M, Chan E. Lysosomotropism depends on glucose: a chloroquine resistance mechanism. Cell Death Dis. 2017;8:e3014 pubmed publisher
Tavangar F, Sepehri H, Saghaeian Jazi M, Asadi J. Amphotericin B potentiates the anticancer activity of doxorubicin on the MCF-7 breast cancer cells. J Chem Biol. 2017;10:143-150 pubmed publisher
Beak J, Huang W, Parker J, Hicks S, Patterson C, Simpson P, et al. An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity. JACC Basic Transl Sci. 2017;2:39-53 pubmed publisher
Yuan H, Tan B, Gao S. Tenovin-6 impairs autophagy by inhibiting autophagic flux. Cell Death Dis. 2017;8:e2608 pubmed publisher
Montgomery M, Chan T, Swigart P, Myagmar B, Dash R, Simpson P. An Alpha-1A Adrenergic Receptor Agonist Prevents Acute Doxorubicin Cardiomyopathy in Male Mice. PLoS ONE. 2017;12:e0168409 pubmed publisher
Thomas R, Singh A, Cowley P, Myagmar B, Montgomery M, Swigart P, et al. A Myocardial Slice Culture Model Reveals Alpha-1A-Adrenergic Receptor Signaling in the Human Heart. JACC Basic Transl Sci. 2016;1:155-167 pubmed
Thomas R, Cowley P, Singh A, Myagmar B, Swigart P, Baker A, et al. The Alpha-1A Adrenergic Receptor in the Rabbit Heart. PLoS ONE. 2016;11:e0155238 pubmed publisher
Aho J, Helenius M, Vattulainen Collanus S, Alastalo T, Koskenvuo J. Extracellular ATP protects endothelial cells against DNA damage. Purinergic Signal. 2016;12:575-81 pubmed publisher
Bussey K, Bapat A, Linnehan C, Wandoloski M, Dastrup E, Rogers E, et al. Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clin Transl Med. 2016;5:1 pubmed publisher
Hayano M, Yang W, Corn C, Pagano N, Stockwell B. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ. 2016;23:270-8 pubmed publisher
Zhitomirsky B, Assaraf Y. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 2015;6:1143-56 pubmed
Smyth T, Kullberg M, Malik N, Smith Jones P, Graner M, Anchordoquy T. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release. 2015;199:145-55 pubmed publisher
Sundaresan V, Menon J, Rahimi M, Nguyen K, Wadajkar A. Dual-responsive polymer-coated iron oxide nanoparticles for drug delivery and imaging applications. Int J Pharm. 2014;466:1-7 pubmed publisher
Robinson T, Liu J, Vizeacoumar F, Sun T, MacLean N, Egan S, et al. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS ONE. 2013;8:e78641 pubmed publisher
Gharanei M, Hussain A, Janneh O, Maddock H. Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. PLoS ONE. 2013;8:e77713 pubmed publisher
Gligorich K, Vaden R, Shelton D, Wang G, Matsen C, Looper R, et al. Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells. Breast Cancer Res. 2013;15:R58 pubmed
Toldo S, Goehe R, Lotrionte M, Mezzaroma E, Sumner E, Biondi Zoccai G, et al. Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. PLoS ONE. 2013;8:e58421 pubmed publisher
Natrajan R, Mackay A, Wilkerson P, Lambros M, Wetterskog D, Arnedos M, et al. Functional characterization of the 19q12 amplicon in grade III breast cancers. Breast Cancer Res. 2012;14:R53 pubmed
Lim Y, Park T, Lim I. B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage. J Biol Chem. 2008;283:33110-8 pubmed publisher

product information

brand :

Tocris, a Bio-Techne brand

catalog number base :

2252

SKU :

2252/10

product name :

Doxorubicin hydrochloride

description :

Antitumor antibiotic agent. Inhibits DNA topoisomerase II

target :

DNA Topoisomerase Inhibitors

unit size :

10 mg (also 50 mg)

category :

Small Molecules

purity :

98%

storage :

Desiccate at RT

observed molecular weight :

579.99

url print :

?utm_source=biocompare&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

details of functionality :

Doxorubicin hydrochloride is a 14-hydroxylated version of Daunorubicin (Cat. No. 1467) that is naturally fluorescent. Doxorubicin is an antitumor antibiotic agent that inhibits DNA topoisomerase II. It is a DNA intercalator that inhibits nucleic acid synthesis and induces apoptosis. Doxorubicin reduces intracellular tau levels. Doxorubicin also promotes formation of free radicals for the disruption of membrane lipids and DNA strands. Doxorubicin fluorescence is quenched upon intercalation into the DNA; while binding to histones or partitioning into the phospholipid phase of PEG-phospholipid micelles or hydrophobic cores of polymeric micelles, increases Doxorubicin fluorescence. Doxorubicin fluorescence enables the monitoring of the localization of the drug within lipid bilayers and liposomal delivery systems and interaction of the drug with DNA and other macromolecules, as well as drug efflux pump activities.

product keywords :

Antitumor antibiotics agent inhibitors inhibits DNA topoisomerase II Isomerases NSC123127 chemotherapeutics fluorescence drug efflux pump Adriamycin NSC 123127 DNA Topoisomerase Apoptosis Inducers Antibiotics 2252,

extended description :

Antitumor antibiotic agent. Inhibits DNA topoisomerase II

chemical name text :

10-[(3-Amino-2,3,6-trideoxy- -L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-5,12-naphthacenedione hydrochloride

formula :

C27H29NO11.HCl

formula text :

C27H29NO11.HCl

cas num :

25316-40-9

USD :

202

USD 2025 :

211 USD

product details :

Antitumor antibiotic agent. Inhibits DNA topoisomerase II

alt names :

Adriamycin,NSC 123127

more info or order :

Tocris Bioscience product webpage